Background Vedolizumab specifically recognises the α4β7 integrin and selectively blocks
gut lymphocyte trafficking: potentially, it offers gut‐specific immunosuppression. Aim To …

Background: Vedolizumab is a humanized monoclonal antibody that inhibits gut-selective
α4β7 integrins on the surface of leukocytes, preventing their trafficking into the …

Vedolizumab is a monoclonal antibody to the α4β7 integrin that selectively reduces
intestinal lymphocyte trafficking, thereby providing a safe and effective treatment option for …

Background Vedolizumab, a gut‐selective α4β7 integrin antibody, is approved for
moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). Aim To report …

Background Vedolizumab (ENTYVIO) is a humanized α4β7 integrin antagonist approved for
the treatment of inflammatory bowel disease, which selectively blocks gut-specific …

Vedolizumab (VDZ), a humanized monoclonal antibody that selectively targets α4β7
integrin, is approved for use in inflammatory bowel disease (IBD). Here we review the …

ABSTRACT Introduction Vedolizumab (Entyvio) is a humanized monoclonal antibody that
disrupts the interaction between α4β7 integrin on circulating T-lymphocytes and MAdCAM-1 …

PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory B... : Medicine PRISMA—Efficacy
and Safety of Vedolizumab for Inflammatory Bowel Diseases: A Systematic Review and …

Objective Vedolizumab is a gut-selective antibody to α4β7 integrin for the treatment of
ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the …

Introduction: Vedolizumab was recently approved by the Food and Drug Administration for
the treatment of moderate to severe ulcerative colitis [UC] and Crohn's disease [CD]. No …